𝔖 Bobbio Scriptorium

✦ LIBER ✦

The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer

✍ Scribed by W.K. Evans; T. Le Chevalier

Book ID: 117663564
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 821 KB
Volume: 32
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(96)00298-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN71 COST-EFFECTIVENESS OF ORALTOPOTECA

PCN71 COST-EFFECTIVENESS OF ORALTOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED SMALL–CELL LUNG CANCER (SCLC) IN THE UK

✍ K Lykopoulos; S Morris; N Papo; ME O'Brien 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

O-11 Estimating the financial cost of su

O-11 Estimating the financial cost of supportive care plus cisplatin-based chemotherapy compared with supportive care alone in the treatment of patients with advanced non-small cell lung cancer (NSCLC) using data from the big lung trial (BLT)

✍ West, Peter; Maslove, Lisa; Gower, Nicole; Stephens, Richard J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB

Percutaneous Fine-Needle 5% Ethanol-Cisp

Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non–Small Cell Lung Cancer

✍ Niu, Qi; Wang, Wei; Li, Qian; Li, Yong; Ruden, Douglas M.; He, Baoming 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 500 KB

PCN2I A PHARMACOECONOMIC MODEL OF THE CO

PCN2I A PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB (“IRESSA”) COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) IN THE UK

✍ AE Ratcliffe; SM Beard; S Wolowacz 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB